Rallybio (NASDAQ:RLYB – Get Free Report) is expected to be announcing its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.27) per share for the quarter.
Rallybio Stock Performance
Shares of RLYB stock opened at $0.74 on Friday. The stock’s fifty day moving average price is $0.84 and its two-hundred day moving average price is $0.99. The company has a market cap of $30.87 million, a PE ratio of -0.46 and a beta of -1.45. Rallybio has a fifty-two week low of $0.68 and a fifty-two week high of $3.46.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reaffirmed a “buy” rating and issued a $5.00 target price on shares of Rallybio in a report on Wednesday, February 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.75.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Articles
- Five stocks we like better than Rallybio
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- What Are Treasury Bonds?
- 3 Stocks to Buy While Others Stay on the Sidelines
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.
